According to an update by the World Health Organization, as of Friday there have been 2,615 confirmed cases of the disease and 1,427 deaths.

On Friday, WHO issued a statement explaining how the fast-moving outbreak has been significantly underestimated, particularly in Liberia and Sierra Leone.

The statement cites as contributing factors both fear of western health care workers and the stigma of being placed in isolation at one of the quarantine centers, which recent reports described as having limited access to food and health care and resembling the “plague villages” of medieval Europe.

WHO issued an additional statement on Monday calling attention to the “unprecedented” number of health care workers who have been infected with the virus, citing a lack of protective equipment and early misdiagnosis at health treatment centers.

Japan is reportedly waiting for WHO approval to provide thousands of doses of the anti-influenza drug favipiravir, known as Avigan, for the possible treatment of Ebola.

Though Avigan has not been proven to be effective against Ebola, Takao Aoki, spokesman for Fujifilm Holdings Corp which developed the drug, said Ebola and influenza viruses are the same general type, and a similar response can theoretically be expected from Ebola.

According to Aoki, the company has enough stock of favipiravir for more than 20,000 patients.

Our work is licensed under a Creative Commons Attribution-Share Alike 3.0 License. Feel free to republish and share widely.

Leave a Reply

Your email address will not be published. Required fields are marked *